FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy

Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating FOXO1. Despite of the clinical relevance of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyrzynska, Beata, Dwojak, Michal, Zerrouqi, Abdessamad, Morlino, Giulia, Zapala, Piotr, Miazek, Nina, Zagozdzon, Agnieszka, Bojarczuk, Kamil, Bobrowicz, Malgorzata, Siernicka, Marta, Machnicki, Marcin M., Gobessi, Stefania, Barankiewicz, Joanna, Lech-Maranda, Ewa, Efremov, Dimitar G., Juszczynski, Przemyslaw, Calado, Dinis, Golab, Jakub, Winiarska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927521/
https://www.ncbi.nlm.nih.gov/pubmed/29721381
http://dx.doi.org/10.1080/2162402X.2017.1423183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927521/
https://www.ncbi.nlm.nih.gov/pubmed/29721381
http://dx.doi.org/10.1080/2162402X.2017.1423183

Ejemplares similares